Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
8
×
life sciences
national blog main
new york blog main
8
×
boston blog main
boston top stories
new york top stories
national top stories
san diego blog main
biotech
fda
indiana blog main
san diego top stories
san francisco blog main
indiana top stories
raleigh-durham blog main
san francisco top stories
seattle blog main
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
raleigh-durham top stories
seattle top stories
texas blog main
texas top stories
type 1 diabetes
wisconsin blog main
wisconsin top stories
akcea therapeutics
boston
boston university
cancer
deals
diabetes
drugs
eli lilly
europe blog main
What
patients
8
×
drug
fda
ago
alnylam
approved
bio
diabetes
disease
friday
help
market
medicine
new
roundup
sets
type
acorda
advantages
akcea
amyloidosis
approval
approve
aren’t
attr
available
awaits
bar
battle
beta
bid
biological
bionics
blood
boehringer
brings
cancer
closed
cope
crossed
Language
unset
Current search:
patients
×
" clinical trials "
×
" new york blog main "
×
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision